BRVE
- GlobeNewswire
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart ...
- GlobeNewswire
Braveheart Bio to Participate in Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ...
- Analyst Upgrades
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio with a Buy rating and announces Price Target of $48. ...
- Analyst Upgrades
TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on Braveheart Bio with a Buy rating. ...
- Analyst Upgrades
Jefferies Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Jefferies initiates coverage on Braveheart Bio with a Buy rating and announces Price Target of $48. ...
- Analyst Upgrades
Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio with a Overweight rating and announces Price Target of $40. ...
- Analyst Upgrades
Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45
Stifel analyst James Condulis initiates coverage on Braveheart Bio with a Buy rating and announces Price Target of $45. ...
- GlobeNewswire
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ...
- GlobeNewswire
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ...